Genelux Corp - GNLX STOCK NEWS

Genelux (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, has announced its participation in the H.C. Wainwright Global Healthcare Conference from September 9-11, 2024, in New York City. Thomas Zindrick, President, Chairman and CEO, will engage in a fireside chat with Emily Bodnar, Vice President of Equity Research and H.C. Wainwright Biotechnology Analyst, on September 11 at 12:30 p.m. ET.

The presentation will cover Genelux's clinical-stage programs, recent announcements, and upcoming milestones. A webcast of the event will be available, with an archived replay accessible for approximately 90 days on the company's IR page. Genelux will also participate in virtual one-on-one meetings during the conference, offering institutional investors the opportunity to engage directly with management.

Genelux (NASDAQ: GNLX) reported its Q2 2024 financial results and provided business updates. The company completed a $30 million public offering, providing runway through three trial readouts. Genelux anticipates interim results from the Phase 2 trial in recurrent non-small cell lung cancer by mid-2025 and interim data from the Phase 1b trial in recurrent small cell lung cancer later this year. The ongoing Phase 3 OnPrime/GOG-3076 trial in platinum-resistant/refractory ovarian cancer continues enrollment with topline results expected in H2 2025.

Financial highlights include:

• Cash, cash equivalents, and investments of $40.4 million as of June 30, 2024
• R&D expenses increased to $4.4 million in Q2 2024
• G&A expenses remained flat at $2.5 million
• Net loss of $6.6 million or $0.22 per share

Genelux (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, has announced its participation in BTIG's Virtual Biotechnology Conference 2024. The company's President, CEO, and Chairman, Thomas Zindrick, will engage in a fireside chat with Kaveri Pohlman, PhD, Director and BTIG Biotechnology Analyst. The discussion is scheduled for Tuesday, August 6, 2024, at 12:00 p.m. ET.

During the chat, Zindrick will provide insights into Genelux's clinical-stage programs, recent announcements, and upcoming milestones. This event presents an opportunity for investors and industry professionals to gain valuable information about Genelux's progress and future plans in the immuno-oncology field.

Genelux (Nasdaq: GNLX), an immuno-oncology company, has announced the pricing of an underwritten offering of 6,875,000 shares of common stock and accompanying warrants at $4.00 per share and warrant. Each warrant will have an exercise price of $5.25. The gross proceeds are expected to be approximately $27.5 million, with net proceeds providing working capital into Q1 2026. The funds will support the clinical development of Olvi-Vec, with Phase 3 trial results anticipated in H2 2025. The offering is expected to close around May 29, 2024. Guggenheim Securities and Newbridge Securities are managing the offering. A 30-day option for an additional 1,031,250 shares and warrants is also included.

Genelux (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, has announced a proposed public offering of its common stock and accompanying warrants. This offering is underwritten, with Guggenheim Securities acting as the sole book-running manager and Newbridge Securities as the co-manager. Genelux plans to grant underwriters a 30-day option to purchase an additional 15% of the shares sold.

The offering is backed by an effective shelf registration statement filed with the SEC, and a preliminary prospectus supplement will be filed. The completion of the offering is subject to market conditions and other customary closing conditions.

Genelux reported its first-quarter 2024 financial results and provided updates on its business activities. The company is progressing with its pivotal Phase 3 registration trial of Olvi-Vec in platinum resistant/refractory ovarian cancer and plans to expand its use into other cancer indications. Genelux is also enrolling patients in clinical trials for non-small cell lung cancer and recurrent small cell lung cancer. The company filed a shelf registration statement to offer up to $300.0 million in common stock, preferred stock, debt securities, and warrants. Financially, Genelux had $19.6 million in cash, cash equivalents, and short-term investments as of March 31, 2024. Research and development expenses increased by $1.2 million year-over-year, while general and administrative expenses increased by $0.3 million in the first quarter of 2024.

Genelux (GNLX) reported fourth quarter and full year 2023 financial results, highlighting active enrollment in pivotal Phase 3 trials for platinum resistant ovarian cancer and advancements in lung cancer trials. The company holds $23.2 million in cash and investments. With ongoing clinical trials, Genelux aims to enhance cancer treatment options and offer hope to patients.

Genelux Corporation (GNLX) initiates pivotal Phase 3 study of Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer. The Phase 2 trial demonstrated clinical reversal of platinum resistance and refractoriness, meeting the primary endpoint of objective response rate with durable responses. The FDA has granted Fast Track designation for the development program of Olvi-Vec for the treatment of patients with platinum resistant/refractory ovarian cancer.

Genelux Corporation (NASDAQ: GNLX) announced the appointment of Lourie Zak as Chief Financial Officer and an extended clinical focus on systemic administration in small cell lung cancer. The company reported $29.9 million in cash and equivalents for the third quarter of 2023, highlighting pipeline advancements and business updates.